Claims

1. A compound represented by the formula:



(I)

wherein

ring A is an optionally substituted aromatic ring;

X is CH or N

or a salt thereof.

2. The compound according to claim 1, wherein the ring A is a C_{6-14} aromatic hydrocarbon ring or a 5- to 14-membered aromatic heterocycle, each of which is optionally substituted by 1 to 3 substituents selected from

(a) a halogen atom,

(b) a cyano group,

(c) a carbamoyl group,

(d) an optionally halogenated C_{1-6} alkyl group,

(e) a C_{1-6} alkoxy group,

(f) a C_{3-10} cycloalkyl group, and

(g) a C_{7-16} aralkyloxy group,

or a salt thereof.

3. 4-((3,5-Dichloropyridin-2-yl)oxy)-2'-oxo-1',2'-dihydrospiro[cyclohexane-1,3'-indole]-5'-carboxylic acid or a salt thereof.

4. 4-((3,5-dichloropyridin-2-yl)oxy)-2'-oxo-1',2'-

dihydrospiro[cyclohexane-1,3'-pyrrolo[3,2-b]pyridine]-5'-carboxylic acid or a salt thereof.

5. 2'-oxo-4-(2,4,6-trichlorophenoxy)-1',2'-dihydrospiro[cyclohexane-1,3'-indole]-5'-carboxylic acid or a salt thereof.

6. 4-(2,4-dichlorophenoxy)-2'-oxo-1',2'-dihydrospiro[cyclohexane-1,3'-indole]-5'-carboxylic acid or a salt thereof.

7. 4-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2'-oxo-1',2'-dihydrospiro[cyclohexane-1,3'-indole]-5'-carboxylic acid or a salt thereof.

8. 4-(4-chloro-2-methoxyphenoxy)-2'-oxo-1',2'-dihydrospiro[cyclohexane-1,3'-indole]-5'-carboxylic acid or a salt thereof.

9. 4-((5-chloro-3-fluoropyridin-2-yl)oxy)-2'-oxo-1',2'-dihydrospiro[cyclohexane-1,3'-indole]-5'-carboxylic acid or a salt thereof.

10. 4-(2,4-dichlorophenoxy)-2'-oxo-1',2'-dihydrospiro[cyclohexane-1,3'-pyrrolo[3,2-b]pyridine]-5'-carboxylic acid or a salt thereof.

11. 4-((3-chloro-5-(trifluoromethyl)pyridin-2-yl)oxy)-2'-oxo-1',2'-dihydrospiro[cyclohexane-1,3'-pyrrolo[3,2-b]pyridine]-5'-carboxylic acid or a salt thereof.

12. A medicament comprising the compound according to claim 1 or a salt thereof.

13. The medicament according to claim 12, which is an inositol hexakisphosphate kinase inhibitor.

14. The medicament according to claim 12, which is a prophylactic or therapeutic agent for a disease selected from cardiac failure and diabetes.

15. The compound according to claim 1 or a salt thereof for use in inhibiting inositol hexakisphosphate kinase in a mammal, wherein an effective amount of the compound according to claim 1 or a salt thereof is to be administered to the mammal.

16. Use of the compound according to claim 1 or a salt thereof in the manufacture of a medicament for the prophylaxis or treatment of a disease selected from cardiac failure and diabetes.

17. The compound according to claim 1 or a salt thereof for use in the prophylaxis or treatment of a disease selected from cardiac failure and diabetes.

18. The compound according to claim 1 or a salt thereof for use in medicine.